UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Harnessing the Breakthroughs in Lung Cancer Treatment: "We still have some challenging issues."

Oncology (Williston Park, N.Y.), 2020-12, Vol.34 (12), p.536

Lilenbaum, Rogerio C

2020

Volltextzugriff (PDF)

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes

Journal of clinical oncology, 2014-04, Vol.32 (12), p.1277-1280

2014

Volltextzugriff (PDF)

Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2

Journal of clinical oncology, 2013-08, Vol.31 (23), p.2849-2853

2013

Volltextzugriff (PDF)

Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3320-3326

2013

Volltextzugriff (PDF)

Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR -Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403

Journal of clinical oncology, 2020-12, Vol.38 (34), p.4076-4085

2020

Volltextzugriff (PDF)

Small Cell Lung Cancer: Past, Present, and Future

Current oncology reports, 2010-09, Vol.12 (5), p.327-334

2010

Volltextzugriff (PDF)

Prevalence of Poor Performance Status in Lung Cancer Patients: Implications for Research

Journal of thoracic oncology, 2008-02, Vol.3 (2), p.125-129

2008

Volltextzugriff (PDF)

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2010-11, Vol.28 (33), p.4953-4960

2010

Volltextzugriff (PDF)

Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer

Journal of clinical oncology, 2015-12, Vol.33 (36), p.4240-4246

2015

Volltextzugriff (PDF)

Single-Agent Versus Combination Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730)

Journal of clinical oncology, 2005-01, Vol.23 (1), p.190-196

2005

Volltextzugriff (PDF)

Treatment of Elderly Patients With Non–Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology

Clinical lung cancer, 2015-09, Vol.16 (5), p.325-333

2015

Volltextzugriff (PDF)

Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2

Journal of clinical oncology, 2008-02, Vol.26 (6), p.863-869

2008

Volltextzugriff (PDF)

Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Right Treatment for the Right Patient

Journal of clinical oncology, 2016-05, Vol.34 (13), p.1438-1442

2016

Volltextzugriff (PDF)

Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer

Journal of the National Comprehensive Cancer Network, 2016-05, Vol.14 (5 Suppl), p.672-674

2016

Volltextzugriff (PDF)

Phase II Trial of Cetuximab in Patients With Previously Treated Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2006-11, Vol.24 (33), p.5253-5258

2006

Volltextzugriff (PDF)

Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non–Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711)

Journal of thoracic oncology, 2018-07, Vol.13 (7), p.996-1003

2018

Volltextzugriff (PDF)

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2018-03, Vol.117, p.44-49

2018

Volltextzugriff (PDF)

Randomized Phase II Trial of Docetaxel Plus Cetuximab or Docetaxel Plus Bortezomib in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2: CALGB 30402

Journal of clinical oncology, 2009-09, Vol.27 (27), p.4487-4491

2009

Volltextzugriff (PDF)

MTE27.01 Treatment of Lung Cancer Patients with Poor Performance Status

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S179-S180

Lilenbaum, Rogerio

2017

Volltextzugriff (PDF)

Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer

Chest, 2003-01, Vol.123 (1), p.226S-243S

2003

Volltextzugriff (PDF)

Stereotactic Body Radiotherapy in Patients With Stage I Non–Small-Cell Lung Cancer Aged 75 Years and Older: Retrospective Results From a Multicenter Consortium

Clinical lung cancer, 2013-07, Vol.14 (4), p.446-451

2013

Volltextzugriff (PDF)

New Horizons in Chemotherapy: Platforms for Combinations in First-Line Advanced Non-small Cell Lung Cancer

Journal of thoracic oncology, 2008-06, Vol.3 (6), p.S171-S174

Lilenbaum, Rogerio C.

2008

Volltextzugriff (PDF)

The Evolving Role of Cetuximab in Non–Small Cell Lung Cancer

Clinical cancer research, 2006-07, Vol.12 (14), p.4432s-4435s

LILENBAUM, Rogerio C

2006

Volltextzugriff (PDF)

Randomized Phase II Trial of Docetaxel/Irinotecan and Gemcitabine/Irinotecan With or Without Celecoxib in the Second-Line Treatment of Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2006-10, Vol.24 (30), p.4825-4832

2006

Volltextzugriff (PDF)

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6

Journal of thoracic oncology, 2007-06, Vol.2 (6), p.494-498

2007

Volltextzugriff (PDF)

1 – 25 von 148

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(137)
Mit Volltextzugriff
(131)

Publikationsform

Sprache

Englisch
(148)

Erscheinungsjahr

n.n

Thema

Humans
(96)
Life Sciences & Biomedicine
(86)
Science & Technology
(86)
Oncology
(79)
Lung Neoplasms - Drug Therapy
(52)
Aged
(48)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(48)
Male
(48)
Female
(47)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(41)
Biological And Medical Sciences
(36)
Medical Sciences
(36)
Middle Aged
(35)
Lung Neoplasms - Pathology
(34)
Chemotherapy
(29)
Carcinoma, Non-Small-Cell Lung - Pathology
(27)
Treatment Outcome
(25)
Aged, 80 And Over
(24)
Adult
(22)
Clinical Trials As Topic
(22)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Harnessing the Breakthroughs in Lung Cancer Treatment: "We still have some challenging issues."

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes

Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2

Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study

Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR -Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403

Small Cell Lung Cancer: Past, Present, and Future

Prevalence of Poor Performance Status in Lung Cancer Patients: Implications for Research

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer

Single-Agent Versus Combination Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730)

Treatment of Elderly Patients With Non–Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology

Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2

Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Right Treatment for the Right Patient

Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer

Phase II Trial of Cetuximab in Patients With Previously Treated Non–Small-Cell Lung Cancer

Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non–Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711)

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer

Randomized Phase II Trial of Docetaxel Plus Cetuximab or Docetaxel Plus Bortezomib in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2: CALGB 30402

MTE27.01 Treatment of Lung Cancer Patients with Poor Performance Status

Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer

Stereotactic Body Radiotherapy in Patients With Stage I Non–Small-Cell Lung Cancer Aged 75 Years and Older: Retrospective Results From a Multicenter Consortium

New Horizons in Chemotherapy: Platforms for Combinations in First-Line Advanced Non-small Cell Lung Cancer

The Evolving Role of Cetuximab in Non–Small Cell Lung Cancer

Randomized Phase II Trial of Docetaxel/Irinotecan and Gemcitabine/Irinotecan With or Without Celecoxib in the Second-Line Treatment of Non–Small-Cell Lung Cancer

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6

Suchergebnisse filtern